• Palisade Bio released new clinical and translational results for PALI-2108, already presented in five posters at ACG 2026.
• Small early-stage studies in ulcerative colitis showed rapid symptom improvement with biopsy findings consistent with reduced intestinal inflammation.
• A separate early Crohn’s cohort showed early endoscopic improvement with biomarker shifts suggesting anti-inflammatory activity; fibrosis reversal was not established.
• Pharmacokinetic work supported once-daily dosing, backed by evidence of targeted intestinal drug exposure with sustained systemic levels.
• Program updates supported ongoing Phase 2 trials in ulcerative colitis and Crohn’s disease, including ASCENTRA-UC enrolling about 204 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120805PRIMZONEFULLFEED9843660) on October 12, 2026, and is solely responsible for the information contained therein.